14.38
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
What drives Keros Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com
Is Keros Therapeutics Inc. a good long term investmentTremendous portfolio expansion - jammulinksnews.com
What analysts say about Keros Therapeutics Inc. stockTremendous gains - jammulinksnews.com
Keros Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital gains - Autocar Professional
(KROS) Trading Signals - news.stocktradersdaily.com
Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser
Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks
Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com South Africa
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times
Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com
Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser
How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser
What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat
Trend Tracker for (KROS) - news.stocktradersdaily.com
Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener
(KROS) Trading Report - news.stocktradersdaily.com
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat
Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga
Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener
ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize
BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):